Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients

Fig. 5

Senescence status of aMSC. Unpaired Student's t-test of cell cycle inhibitor markers transcript numbers. (a) The median values of TBP for IPFaMSC and HCaMSC were 2691 and 2447 transcript number/cell, respectively. (b) The median values of the normalized (RB1/TBP) ratio for IPFaMSC and HCaMSC were 3.72 and 3.89 transcript numbers/cell, respectively. (c) The median values of the normalized (TP53/TBP) ratio for IPFaMSC and HCaMSC were 1.04 and 0.93 transcript /cell, respectively. (d) The median values of the normalized (CDKN1/TBP) ratio for IPFaMSC and HCaMSC were 1.48 and 3.71 transcript number/cell, respectively. (e) The median values of the (p16ink4a/TBP) ratio for IPFaMSC and HCaMSC were 0.1 and 0.7 transcript numbers/cell. The CV% between triplicates was less than 15% for all tested cell cycle inhibitor marker transcripts. No significant difference between two tested cell groups was found in normalized transcript numbers of cell cycle markers inhibitors. Dots represent individual cell line values. Differences were considered significant when *p < 0.05, compared with control cell lines

Back to article page